Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Fig. 1: Flow cytometric profiles and outcome of patients with classical CMML and flow cytometry-defined inflammatory CMML. References 1. Orazi A, Bennett JM, Germing U, Brunning RD, Bain BJ, Cazzola M, et al. Chronic myelomonocytic leukemia. In: WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2017. p. 81–6. 2. Selimoglu-Buet D, Wagner-Ballon O, Saada V, Bardet V, Itzykson R, Bencheikh L, et al.
Highlights: • This ESMO Clinical Practice Guideline provides key recommendations for managing myelodysplastic syndromes • It covers diagnosis, classification, staging and risk assessment of myelodysplastic syndromes • Treatment recommendations for lower- and higher-risk myelodysplastic syndromes are also provided • All recommendations were compiled by a multidisciplinary group of experts • Recommendations are based on available scientific data and the authors’ expert opinion Key words...
Myelodysplastic syndromes (MDS) are clonal haematopoietic stem cell (HSC) disorders predominating in the elderly, characterised by ineffective haematopoiesis leading to blood cytopaenias and by progression to acute myeloid leukaemia (AML) in one-third of cases [1]. Their pathophysiology is a multistep process involving cytogenetic changes and/or gene mutations [2] and widespread gene hypermethylation at advanced stages [3–5].
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
